P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1864
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports
Multidisciplinary
2017English

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-08 Assessment of EGFR Gene Mutations in Cf-Dna in Monitoring of Response to EGFR TKIs in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2019English

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy